Clearly, Nrf2 plays a significant role in both anti-lung cancer treatment and resistance, indicating that Nrf2 inhibitors combined with other medications could be part of a successful treatment plan for lung cancer. This evidence concerns the gene NFE2L2 and lung carcinoma.